Merck, Glenmark Can’t Shake Zetia Pay-For-Delay MDL

Drugmakers Merck & Co Inc. and Glenmark Pharmaceuticals Ltd. lost a bid to kill multidistrict litigation alleging a pay-for-delay scheme involving the cholesterol medication Zetia when a Virginia federal judge on Thursday said an arbitration clause in Merck’s contracts with customers improperly waived their statutory rights, making it unenforceable…

Read this piece in its entirety at Law360.

Comments

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s